SCHEMBL6740356

SCHEMBL6740356

CC(C)(C)OC(=O)[C@@H](CN1C(=O)c2ccccc2C1=O)NS(=O)(=O)Cc1ccc2sccc2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
BRD4 O60885 1/20 0.33
STS P08842 1/20 0.33
PER2 O15055 1/20 0.32
CRY1 Q16526 1/20 0.32
CRY2 Q49AN0 1/20 0.32
P2RX3 P56373 1/20 0.32
PTPN1 P18031 1/20 0.32
PTGER3 P43115 1/20 0.32
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
MAOA P21397 1/20 0.31
MMP13 P45452 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
PTPRC P08575 2/20 0.31
HPGD P15428 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6740361 1.00 ALDH1A1 (0.34) ALDH1A1TSHRHTTNPSR1BRD4
SCHEMBL7061407 0.86 ITGAV (0.37) BRD4PER2CRY1CRY2PTGER3
SCHEMBL7061415 0.86 ITGAV (0.37) BRD4PER2CRY1CRY2PTGER3
SCHEMBL6739588 0.85 MMP2 (0.41) BRD4PTGER3MMP13
SCHEMBL6740111 0.85 MMP2 (0.41) BRD4PTGER3MMP13
SCHEMBL7126321 0.82 NPR3 (0.39) ALDH1A1NPSR1MMP13POLB
SCHEMBL6732763 0.80 SIGMAR1 (0.34) STSMMP13
SCHEMBL7117234 0.79 CTNNB1 (0.36) STSMMP13
SCHEMBL7127966 0.77 ATM (0.35) STSMMP13
SCHEMBL6742137 0.75 ALDH1A1 (0.39) ALDH1A1TSHRNPSR1GLAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040225006-A1 (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates SMITHKLINE BEECHAM P.L.C. 2004-11-11 US disclosed
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-23 US disclosed
EP-1244616-A1 (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SmithKline Beecham plc (GB) 2002-10-02 EP disclosed
WO-2001047874-A1 (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SMITHKLINE BEECHAM P.L.C. (GB) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives CD40, CD22, CD2 ALDH1A1 350/4885TSHR 974/4885HTT 2481/4885
US-20040225006-A1 (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates CD40, TNFRSF1A, CD2 ALDH1A1 139/4885TSHR 952/4885HTT 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.